Citation Impact
Citing Papers
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
2009
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
2014 Standout
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
2011 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
2005
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases
2004
FGFR3 mutations in prostate cancer: association with low-grade tumors
2009
The FGF family: biology, pathophysiology and therapy
2009 Standout
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Neurotoxicity of calcineurin inhibitors: impact and clinical management
2000
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
1998 Standout
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision
2010 Standout
Cushing's syndrome
2015 Standout
Guidelines on Bladder Cancer
2002
Guillain-Barré syndrome
2016 Standout
Initial High-Grade T1 Urothelial Cell Carcinoma: Feasibility and Prognostic Significance of Lamina Propria Invasion Microstaging (T1a/b/c) in BCG-Treated and BCG-Non-Treated Patients
2005
Crohn's disease
2012 Standout
Localized Mucosal Leishmaniasis due to Leishmania (Leishmania) infantum
2003
A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?
2004
Cutaneous leishmaniasis
2007 Standout
Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
2000
Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects
2008
Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease
2010 StandoutNobel
Normal and neoplastic urothelial stem cells: getting to the root of the problem
2012
Decrease of Apoptosis Rate in Patients with Renal Transplantation Treated with Mycophenolate Mofetil
1999
Inflammatory Bowel Disease
2009 Standout
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
2000
Chronic kidney disease
2011 Standout
Fibroblast Growth Factor Receptor 3 Mutations in Epidermal Nevi and Associated Low Grade Bladder Tumors
2007
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Proteinuria in Kidney Transplant Recipients: Prevalence, Prognosis, and Evidence-Based Management
2009
Pathobiology of Pituitary Adenomas and Carcinomas
2006
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
2002
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Calcineurin Inhibitor Avoidance with Daclizumab, Mycophenolate Mofetil, and Prednisolone in DR-Matched de Novo Kidney Transplant Recipients
2006
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Bladder cancer
2016 Standout
A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation
2005
Corticotroph carcinoma of the pituitary: a clinicopathological study
2002
Transplantation-associated thrombotic microangiopathy: twenty-two years later
2002
Mosaicism of activatingFGFR3 mutations in human skin causes epidermal nevi
2006
Immunopathogenesis and treatment of the guillain‐barré syndrome—part I
1995
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
2007 Standout
Portrait of PTEN: Messages from mutant mice
2008 StandoutNobel
Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma
2011
Cyclosporine Avoidance
2000
Mycophenolate mofetil and its mechanisms of action
2000 Standout
A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
2010 Standout
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
2005
Strategies to Improve Long-Term Outcomes after Renal Transplantation
2002 Standout
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Peripheral neuropathy in patients with inflammatory bowel disease
2005
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.
2005
Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study
2008
Sexually transmitted diseases treatment guidelines
2003 Standout
microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3
2011
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
2005
Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis
2003
Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation
2003
Reversal of chronic cyclosporine nephrotoxicity after heart transplantation—potential role of mycophenolate mofetil
2002
The global burden of IBD: from 2015 to 2025
2015 Standout
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans
2005
External Genital Warts: Diagnosis, Treatment, and Prevention
2002
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Genomics: a preview of genomic medicine
2008
Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism.
2002 StandoutNobel
Molecular biology and targeted therapies for urothelial carcinoma
2015
The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study
2005
Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study
2007
PI3K-Akt pathway: Its functions and alterations in human cancer
2004 Standout
Natural History, Recurrence, and Progression in Superficial Bladder Cancer
2006
The Fibroblast Growth Factor signaling pathway
2015 Standout
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
2007 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation
2005
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions
2004
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
2003
Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal
2010 Standout
Nanomaterials and nanoparticles: Sources and toxicity
2007 Standout
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor–Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines
2005
Advances in leishmaniasis
2005 Standout
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
2008
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
Human plasma fibrinogen is synthesized in the liver
2006
Wound Healing: A Cellular Perspective
2018 Standout
Smoking‐gene Interaction and Disease Development: Relevance to Pancreatic Cancer and Atherosclerosis
2005
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Fibroblast Growth Factors and Their Receptors in Transitional Cell Carcinoma
2003
Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas
2006
Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
2014
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
Hematological Problems in Pediatric Intensive Care
2013 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton Protocol
2001 Standout
Works of C Billerey being referenced
Mycophenolate mofetil in cyclosporin-associated thrombotic microangiopathy
1998
Polyneuropathy: an unusual extraintestinal manifestation of Crohn's disease
1989
MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS WITH CYCLOSPORINE-ASSOCIATED NEPHROTOXICITY
1998
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
2001
Fibrinogen Act chain mutation (Arg554 Leu) associated with hereditary renal amyloidosis in a French family
1998
THE PREDICTIVE VALUE OF MUSCULARIS MUCOSAE INVASION AND p53 OVER EXPRESSION ON PROGRESSION OF STAGE T1 BLADDER CARCINOMA
2001
[Protocol for the pathologic examination of cystectomy and cystoprostatectomy specimens. Proposal for a standardized form].
2000
Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up
2002
[Laryngeal leishmaniasis in a patient from the Jura. Unusual cause of epitheloid and giant cell granulomatosis].
1984
[A rare case of severe toxic peripheral neuropathy: poisoning by podophyllin. Apropos of 1 case].
1990
IMMUNOHISTOCHEMICAL DETECTION OF p53 PROTEIN OVEREXPRESSION VERSUS GENE SEQUENCING IN URINARY BLADDER CARCINOMAS
1999
Influence of cigarette smoking on P53 gene mutations in bladder carcinomas.
2001